Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2-3/2014

01.09.2014 | NON-THEMATIC REVIEW

Advances in genomic characterization of circulating tumor cells

verfasst von: Mark Jesus M. Magbanua, John W. Park

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2014

Einloggen, um Zugang zu erhalten

Abstract

Molecular characterization of circulating tumor cells (CTCs) found in the blood of cancer patients offers the potential to provide new insights into the biology of cancer metastasis. However, since they are rare and difficult to isolate, the molecular nature of CTCs remains poorly understood. In this paper, we reviewed a decade’s worth of scientific literature (2003–2013) describing efforts on isolation and genomic analysis of CTCs. The limited number of CTC genomic studies we found attested to the infancy of this field of study. These initial reports, however, provide an important framework for future comprehensive exploration of CTC biology. For CTCs to be broadly accepted as therapeutic targets and biomarkers of metastatic spread, further in-depth molecular characterization is warranted.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9(4), 302–312.CrossRefPubMed
2.
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008). Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer, 8(5), 329–340.CrossRefPubMed
3.
Alix-Panabieres, C., & Pantel, K. (2013). Circulating tumor cells: liquid biopsy of cancer. Clinical Chemistry, 59(1), 110–118.
4.
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., et al. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research, 10(20), 6897–6904.CrossRefPubMed
5.
Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., et al. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology, 20(7), 1223–1229.CrossRefPubMed
6.
Connelly, M., Wang, Y., Doyle, G. V., Terstappen, L., & McCormack, R. (2009). Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute, 101(12), 895. author reply 896–897.CrossRefPubMed
7.
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine, 351(8), 781–791.CrossRefPubMed
8.
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., et al. (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology, 23(7), 1420–1430.CrossRefPubMed
9.
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302–6309.CrossRefPubMed
10.
Danila, D. C., Fleisher, M., & Scher, H. I. (2011). Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research, 17(12), 3903–3912.PubMedCentralCrossRefPubMed
11.
Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., et al. (1998). High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics, 20(2), 207–211.CrossRefPubMed
12.
Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(19), 3213–3221.CrossRefPubMed
13.
Sieuwerts, A. M., Kraan, J., Bolt-de Vries, J., van der Spoel, P., Mostert, B., Martens, J. W., et al. (2009). Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Research and Treatment, 118(3), 455–468.CrossRefPubMed
14.
Talasaz, A. H., Powell, A. A., Huber, D. E., Berbee, J. G., Roh, K. H., Yu, W., et al. (2009). Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proceedings of the National Academy of Sciences of the United States of America, 106(10), 3970–3975.PubMedCentralCrossRefPubMed
15.
Ramskold, D., Luo, S., Wang, Y. C., Li, R., Deng, Q., Faridani, O. R., et al. (2012). Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nature Biotechnology, 30(8), 777–782.PubMedCentralCrossRefPubMed
16.
Barbazan, J., Alonso-Alconada, L., Muinelo-Romay, L., Vieito, M., Abalo, A., Alonso-Nocelo, M., et al. (2012). Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One, 7(7), e40476.PubMedCentralCrossRefPubMed
17.
Stott, S. L., Hsu, C. H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., et al. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 107(43), 18392–18397.PubMedCentralCrossRefPubMed
18.
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450(7173), 1235–1239.PubMedCentralCrossRefPubMed
19.
Ozkumur, E., Shah, A. M., Ciciliano, J. C., Emmink, B. L., Miyamoto, D. T., Brachtel, E., et al. (2013). Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Science Translational Medicine, 5(179), 179ra147.CrossRef
20.
Desitter, I., Guerrouahen, B. S., Benali-Furet, N., Wechsler, J., Janne, P. A., Kuang, Y., et al. (2011). A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Research, 31(2), 427–441.PubMed
21.
Lu, J., Fan, T., Zhao, Q., Zeng, W., Zaslavsky, E., Chen, J. J., et al. (2010). Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. International Journal of Cancer, 126(3), 669–683.CrossRef
22.
Paris, P. L., Kobayashi, Y., Zhao, Q., Zeng, W., Sridharan, S., Fan, T., et al. (2009). Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Letters, 277(2), 164–173.CrossRefPubMed
23.
Yamada, K. M., & Cukierman, E. (2007). Modeling tissue morphogenesis and cancer in 3D. Cell, 130(4), 601–610.CrossRefPubMed
24.
Magbanua, M. J., & Park, J. W. (2013). Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods, 64(2), 114–118.CrossRefPubMed
25.
Mathiesen, R. R., Fjelldal, R., Liestol, K., Due, E. U., Geigl, J. B., Riethdorf, S., et al. (2012). High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. International Journal of Cancer, 131(4), E405–E415.CrossRef
26.
Tan, S. C., & Yiap, B. C. (2009). DNA, RNA, and protein extraction: the past and the present. Journal of Biomedicine and Biotechnology, 2009, 574398.PubMedCentralCrossRefPubMed
27.
Xu, C., Houck, J. R., Fan, W., Wang, P., Chen, Y., Upton, M., et al. (2008). Simultaneous isolation of DNA and RNA from the same cell population obtained by laser capture microdissection for genome and transcriptome profiling. Journal of Molecular Diagnostics, 10(2), 129–134.PubMedCentralCrossRefPubMed
28.
Sieuwerts, A. M., & Jeffrey, S. S. (2012). Multiplex molecular analysis of CTCs. Recent Results in Cancer Research, 195, 125–140.CrossRefPubMed
29.
30.
Smirnov, D. A., Zweitzig, D. R., Foulk, B. W., Miller, M. C., Doyle, G. V., Pienta, K. J., et al. (2005). Global gene expression profiling of circulating tumor cells. Cancer Research, 65(12), 4993–4997.CrossRefPubMed
31.
O'Hara, S. M., Moreno, J. G., Zweitzig, D. R., Gross, S., Gomella, L. G., & Terstappen, L. W. (2004). Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clinical Chemistry, 50(5), 826–835.CrossRefPubMed
32.
Sieuwerts, A. M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F. E., Stouthard, J. M., et al. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research, 17(11), 3600–3618.CrossRefPubMed
33.
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., et al. (2012). Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One, 7(5), e33788.PubMedCentralCrossRefPubMed
34.
Tang, A., Eller, M. S., Hara, M., Yaar, M., Hirohashi, S., & Gilchrest, B. A. (1994). E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. Journal of Cell Science, 107(Pt 4), 983–992.
35.
Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., Tat, M., et al. (2012). mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One, 7(11), e49144.PubMedCentralCrossRefPubMed
36.
Yu, M., Ting, D. T., Stott, S. L., Wittner, B. S., Ozsolak, F., Paul, S., et al. (2012). RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature, 487(7408), 510–513.PubMedCentralCrossRefPubMed
37.
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339(6119), 580–584.PubMedCentralCrossRefPubMed
38.
Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., et al. (2012). Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery, 2(11), 995–1003.PubMedCentralCrossRefPubMed
39.
Chen, C. L., Mahalingam, D., Osmulski, P., Jadhav, R. R., Wang, C. M., Leach, R. J., et al. (2013). Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate, 73(8), 813–826.CrossRefPubMed
40.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed
41.
Klein, C. A., Schmidt-Kittler, O., Schardt, J. A., Pantel, K., Speicher, M. R., & Riethmuller, G. (1999). Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proceedings of the National Academy of Sciences of the United States of America, 96(8), 4494–4499.PubMedCentralCrossRefPubMed
42.
Schmidt-Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blankenstein, T. J., et al. (2003). From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7737–7742.PubMedCentralCrossRefPubMed
43.
Schardt, J. A., Meyer, M., Hartmann, C. H., Schubert, F., Schmidt-Kittler, O., Fuhrmann, C., et al. (2005). Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell, 8(3), 227–239.CrossRefPubMed
44.
Fuhrmann, C., Schmidt-Kittler, O., Stoecklein, N. H., Petat-Dutter, K., Vay, C., Bockler, K., et al. (2008). High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Research, 36(7), e39.PubMedCentralCrossRefPubMed
45.
Holcomb, I. N., Grove, D. I., Kinnunen, M., Friedman, C. L., Gallaher, I. S., Morgan, T. M., et al. (2008). Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Research, 68(14), 5599–5608.PubMedCentralCrossRefPubMed
46.
Weckermann, D., Polzer, B., Ragg, T., Blana, A., Schlimok, G., Arnholdt, H., et al. (2009). Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. Journal of Clinical Oncology, 27(10), 1549–1556.CrossRefPubMed
47.
Pierga, J. Y., Bonneton, C., Vincent-Salomon, A., de Cremoux, P., Nos, C., Blin, N., et al. (2004). Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clinical Cancer Research, 10(4), 1392–1400.CrossRefPubMed
48.
Muller, V., Stahmann, N., Riethdorf, S., Rau, T., Zabel, T., Goetz, A., et al. (2005). Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research, 11(10), 3678–3685.CrossRefPubMed
49.
Wiedswang, G., Borgen, E., Schirmer, C., Karesen, R., Kvalheim, G., Nesland, J. M., et al. (2006). Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. International Journal of Cancer, 118(8), 2013–2019.CrossRef
50.
Magbanua, M. J., Sosa, E. V., Roy, R., Eisenbud, L. E., Scott, J. H., Olshen, A., et al. (2013). Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Research, 73(1), 30–40.PubMedCentralCrossRefPubMed
51.
Magbanua, M. J., Sosa, E. V., Scott, J. H., Simko, J., Collins, C., Pinkel, D., et al. (2012). Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer, 12(1), 78.PubMedCentralCrossRefPubMed
52.
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics, 9(4), 401–406.CrossRefPubMed
53.
Hannemann, J., Meyer-Staeckling, S., Kemming, D., Alpers, I., Joosse, S. A., Pospisil, H., et al. (2011). Quantitative high-resolution genomic analysis of single cancer cells. PLoS One, 6(11), e26362.PubMedCentralCrossRefPubMed
54.
Ulmer, A., Schmidt-Kittler, O., Fischer, J., Ellwanger, U., Rassner, G., Riethmuller, G., et al. (2004). Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clinical Cancer Research, 10(2), 531–537.CrossRefPubMed
55.
Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E. M., et al. (2013). Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Research, 73(10), 2965–2975.CrossRefPubMed
56.
Ni, X., Zhuo, M., Su, Z., Duan, J., Gao, Y., Wang, Z., et al. (2013). Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 110(52), 21083–21088.PubMedCentralCrossRefPubMed
57.
Zong, C., Lu, S., Chapman, A. R., & Xie, X. S. (2012). Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science, 338(6114), 1622–1626.PubMedCentralCrossRefPubMed
58.
Chambers, A. F., Naumov, G. N., Vantyghem, S. A., & Tuck, A. B. (2000). Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Research, 2(6), 400–407.PubMedCentralCrossRefPubMed
59.
Cameron, M. D., Schmidt, E. E., Kerkvliet, N., Nadkarni, K. V., Morris, V. L., Groom, A. C., et al. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Research, 60(9), 2541–2546.PubMed
60.
Wong, C. W., Lee, A., Shientag, L., Yu, J., Dong, Y., Kao, G., et al. (2001). Apoptosis: an early event in metastatic inefficiency. Cancer Research, 61(1), 333–338.PubMed
61.
Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 31(6), 539–544.CrossRefPubMed
62.
Wan, L., Pantel, K., & Kang, Y. (2013). Tumor metastasis: moving new biological insights into the clinic. Nature Medicine, 19(11), 1450–1464.CrossRefPubMed
63.
Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., et al. (2009). Tumor self-seeding by circulating cancer cells. Cell, 139(7), 1315–1326.PubMedCentralCrossRefPubMed
64.
Steinert, G., Scholch, S., Niemietz, T., Iwata, N., Garcia, S. A., Behrens, B., et al. (2014). Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Research, 74(6), 1694–1704.CrossRefPubMed
65.
Howard, E. W., Leung, S. C., Yuen, H. F., Chua, C. W., Lee, D. T., Chan, K. W., et al. (2008). Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clinical & Experimental Metastasis, 25(5), 497–508.CrossRef
66.
Bednarz-Knoll, N., Alix-Panabieres, C., & Pantel, K. (2011). Clinical relevance and biology of circulating tumor cells. Breast Cancer Research, 13(6), 228.PubMedCentralCrossRefPubMed
67.
Gray, J. W. (2003). Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell, 4(1), 4–6.CrossRefPubMed
68.
Park, J. W. (2011). Disseminated tumor cells: the method is the message. Breast Cancer Research and Treatment, 125(3), 739–740.CrossRefPubMed
69.
Plaks, V., Koopman, C. D., & Werb, Z. (2013). Cancer, Circulating tumor cells. Science, 341(6151), 1186–1188.CrossRefPubMed
70.
Sieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., et al. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute, 101(1), 61–66.PubMedCentralCrossRefPubMed
71.
Metadaten
Titel
Advances in genomic characterization of circulating tumor cells
verfasst von
Mark Jesus M. Magbanua
John W. Park
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2-3/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9503-7

Weitere Artikel der Ausgabe 2-3/2014

Cancer and Metastasis Reviews 2-3/2014 Zur Ausgabe

OriginalPaper

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases

OriginalPaper

Immunotherapy for prostate cancer: recent developments and future challenges

CLINICAL

Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy

OriginalPaper

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

OriginalPaper

Emerging technology: applications of Raman spectroscopy for prostate cancer

OriginalPaper

Novel drugs targeting the androgen receptor pathway in prostate cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise